New York S 1755: Establishes a temporary state commission to conduct a feasibility study on the formation and control of a state public bank

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S01755 Summary:

BILL NOS01755 

&nbsp

SAME ASSAME AS A05151

&nbsp

SPONSORPERSAUD

&nbsp

COSPNSRHOYLMAN-SIGAL

&nbsp

MLTSPNSR

&nbsp

Add Art 2 Title 9 §§269-b - 269-d, Pub Health L

&nbsp

Requires any sponsor of a clinical trial in this state, including but not limited to, a pharmaceutical drug manufacturer, pharmaceutical drug wholesaler, academic medical center, voluntary group, federal agency or health care provider, that applies for a state grant to conduct such clinical trial, to conspicuously post certain information about such clinical trial on the department's website.

Go to top S01755 Actions:

BILL NOS01755 

&nbsp

01/13/2025REFERRED TO HEALTH

01/07/2026REFERRED TO HEALTH

Go to topS01755 Committee&nbspVotes:

Go to topS01755 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS01755 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 1755

 2025-2026 Regular Sessions

 IN SENATE

 January 13, 2025
 ___________

 Introduced by Sens. PERSAUD, HOYLMAN-SIGAL -- read twice and ordered
 printed, and when printed to be committed to the Committee on Health

 AN ACT to amend the public health law, in relation to requiring clinical
 trials that apply for state grant funding to make certain information
 about such clinical trials public

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Article 2 of the public health law is amended by adding a
 2 new title 9 to read as follows:
 3 TITLE 9
 4 CLINICAL TRIALS
 5 Section 269-b. Definitions.
 6 269-c. Grant requirements.
 7 269-d. Posting requirements.
 8 § 269-b. Definitions. For purposes of this title:
 9 1. "clinical trial" shall have the same meaning as set forth in subdi-
 10 vision two-b of section forty-nine hundred of this chapter.
 11 2. "health care provider" shall mean a practitioner in an individual
 12 practice, group practice, partnership, professional corporation or other
 13 authorized form of association, a hospital or other health care institu-
 14 tion issued an operating certificate pursuant to this chapter or the
 15 mental hygiene law, a certified home health agency or a licensed home
 16 care services agency, and any other purveyor of health or health related
 17 items or services including but not limited to a clinical laboratory, a
 18 physiological laboratory, a pharmacy, a purveyor of x-ray or imaging
 19 services, a purveyor of physical therapy services, a purveyor of health
 20 or health related supplies, appliances or equipment, or an ambulance
 21 service.
 22 § 269-c. Grant requirements. 1. Following the effective date of this
 23 section, the commissioner shall require any sponsor of a clinical trial
 24 in this state, including but not limited to, a pharmaceutical drug

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD05050-01-5

 S. 1755 2

 1 manufacturer, pharmaceutical drug wholesaler, academic medical center,
 2 voluntary group, federal agency or health care provider, that applies
 3 for a state grant to conduct such clinical trial, to conspicuously post
 4 certain information about such clinical trial on the department's
 5 website.
 6 2. To the extent disclosure is permitted under federal law, the infor-
 7 mation posted in accordance with subdivision one of this section shall
 8 include, but shall not be limited to, the following:
 9 (a) the name of all clinical trial sponsors, funders and manufactur-
 10 ers, including the name and contact information, as well as the institu-
 11 tional affiliation, of all sponsors, co-sponsors and administrators;
 12 (b) a summary of the purpose of the clinical trial, including, but not
 13 limited to: (i) the name of the pharmaceutical drug being tested and its
 14 active ingredients, if applicable; (ii) the type of clinical trial to be
 15 conducted; (iii) the overall design of the study, including the statis-
 16 tical method to be employed; (iv) the status or phase type of the trial;
 17 (v) the inclusion and exclusion criteria; (vi) the treatment methods
 18 used; (vii) all hypotheses tested by the trial; and (viii) the medical
 19 condition or conditions being studied;
 20 (c) the start date and end date of